Safety and Efficacy of AEB071 and EVEROLIMUS in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell Lymphoma
Clinical trial NCT01854606 · COMPLETED
Trial details
- NCT number
- NCT01854606
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2013-12-05
- Primary completion
- 2016-06-01
- Enrollment
- 31
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.